Procyanidin B2
(Synonyms: 原花青素 B2; Proanthocyanidin B2) 目录号 : GN10599A phenol with diverse biological activities
Cas No.:29106-49-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: |
MCF-7 cells are grown in 5 mL of RPMI 1640 medium supplemented with 20% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 μg/mL). Cells are maintained at 37°C in a humidified atmosphere of 5% CO2 in air and subcultured every 3 days. Exponentially growing cells are plated at a seeding density of 2×104 cells/mL, in 96-well plates or in dishes. After overnight incubation to allow for attachment, the cells are exposed for 24 or 48 h to various concentrations of Procyanidin B2 (0.5; 1.0; 5.0; 10.0; 25.0 and 50.0 μM) diluted in distilled water. Two millimolar cyclophosphamide (CP) is used as the positive control and solutions are sterilised by filtration[1]. |
Animal experiment: |
To observe the effect of Procyanidin B2 on infarct size or brain edema, 40 rats are randomLy separated into five groups, and each group is administered with vehicle (equivalent dose of 0.9% saline administered via gavage) or 40, 20, or 10 mg/kg of Procyanidin B2, respectively. To elucidate the effect of Procyanidin B2 on blood-brain barrier (BBB) permeability, the rats (n = 6 per group for Evans blue extravasation and n = 4 per group for IgG leakage) are randomLy separated into two groups: vehicle and Procyanidin B2 (40 mg/kg). Procyanidin B2 (40 mg/kg) is administered intragastrically once a day starting at 3 h after middle cerebral artery occlusion (MCAO). For other observations, including immunohistological staining and western blot analysis, rats are randomLy separated into three groups: sham-operated, vehicle, and Procyanidin B2 (n = 4 per group). Procyanidin B2 (40 mg/kg) is administered intragastrically once a day starting at 3 h after MCAO. To elucidate the improvement in neurological function after ischemic stroke in rats, the rats (n = 8 per group) undergo neurobehavioral assays to evaluate the functional outcome after administration of Procyanidin B2 (40 mg/kg) once a day starting at 24 h after MCAO. The neurological deficits are assessed at 1, 3, 7, 11, and 14 days after MCAO[3]. |
References: [1]. Avelar MM, et al. Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells. Indian J Pharm Sci. 2012 Jul;74(4):351-5. |
Procyanidin B2 is a natural flavonoid, with anti-cancer, antioxidant activities.
Procyanidin B2 shows antiproliferative activity to MCF-7 cells, with an IC50 of 19.21 μM. However, Procyanidin B2 exhibits no effect on DNA-ladder formation[1]. Procyanidin B2 (0.1, 1, 2 μM) inhibits the activation of pyrin domain containing 3 (NLRP3) inflammasome in human umbilical vein ECs (HUVECs), and the inhibition is via suppression of AP-1 activity, and such effect can be abolished by overexpression of c-Jun. Procyanidin B2 (2 μM for 12 h) also reduces ROS in HUVECs[2].
Procyanidin B2 (40, 20, and 10 mg/kg, p.o.) protects against cerebral ischemia-induced infarct volume and brain edema in rats. Procyanidin B2 (40 mg/kg, p.o) also improves functional outcomes, regulates blood-brain barrier (BBB) permeability after cerebral ischemia. Moreover, Procyanidin B2 attenuates cerebral ischemia-induced tight junction degradation, mitochondrial depolarization and intracellular oxidative stress. Procyanidin B2 (40 mg/kg, p.o) increases Nrf2 activation and HO-1, GSTα, and NQO1 protein expression in normal brains in vivo[3].
References:
[1]. Avelar MM, et al. Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells. Indian J Pharm Sci. 2012 Jul;74(4):351-5.
[2]. Yang H, et al. Procyanidin B2 inhibits NLRP3 inflammasome activation in human vascular endothelial cells. Biochem Pharmacol. 2014 Dec 15;92(4):599-606.
[3]. Wu S, et al. Procyanidin B2 attenuates neurological deficits and blood-brain barrier disruption in a rat model of cerebral ischemia. Mol Nutr Food Res. 2015 Oct;59(10):1930-41.
Cas No. | 29106-49-8 | SDF | |
别名 | 原花青素 B2; Proanthocyanidin B2 | ||
化学名 | (2R,3R)-2-(3,4-dihydroxyphenyl)-8-[(2R,3R,4R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromene-3,5,7-triol | ||
Canonical SMILES | C1C(C(OC2=C1C(=CC(=C2C3C(C(OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)O)O)O)C6=CC(=C(C=C6)O)O)O | ||
分子式 | C30H26O12 | 分子量 | 578.52 |
溶解度 | DMF: 30 mg/mL,DMSO: 30 mg/mL,Ethanol: 30 mg/mL,PBS (pH 7.2): 10 mg/mL | 储存条件 | Store at -20℃ |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.7285 mL | 8.6427 mL | 17.2855 mL |
5 mM | 0.3457 mL | 1.7285 mL | 3.4571 mL |
10 mM | 0.1729 mL | 0.8643 mL | 1.7285 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。